IBD posted 18% growth across geographies & likely to continue in near term. We are upgrading MRCO to Accumulate (Hold earlier) as the stock offers value at 34.2xFY24 EPS with ROE/ROCE of 44.8%/55% and ~80% dividend payout post ~19% correction from peak. 3Q volumes disappointed a bit on...